Analysts will also be seeking clarity on any potential impact from the US government’s most favoured nation pricing norms, and on the company’s plans after getting regulatory approval to market semaglutide as a weight-loss drug in India earlier this month.
Sun Pharma Q3FY26 Preview: Innovative portfolio, India market to drive growth
